All blots were reprobed with anti–actin to confirm equal loading, and densitometry was performed using ImageJ software (US National Institutes of Health;http://rsb.info.nih.gov/ij/). == TaqMan gene expression analysis == RNA was extracted using the RNeasy Mini Kit (Qiagen, West Sussex, UK), and converted to cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc. cotreatment of both cell lines with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the DR5 ligand, potentiated the apoptotic response. In NCI-H929 cells, PBOX-15-induced apoptosis was shown to be caspase-8 dependent, with impartial activation of extrinsic and intrinsic apoptotic pathways. A caspase-8-dependent decrease in expression of BimELpreceded downregulation of other Bcl-2 proteins (Bid, Bcl-2, Mcl-1) in PBOX-15-treated NCI-H929 cells. == Conclusion: == PBOX-15 induces apoptosis and potentiates TRAIL-induced cell death in multiple myeloma cells. Thus, PBOX-15 represents a encouraging agent, with a distinct mechanism of action, for the treatment of this malignancy. Keywords:myeloma, caspase-8, DR5, TRAIL, bim Pyrrolo-1,5-benzoxazepine-15 (PBOX-15) is usually a novel tubulin depolymerising agent (Mulliganet al, 2006) that has been shown by us to exhibit proapoptotic activity in a variety of human tumour cell types, including those derived from both solid and haematological malignancies (Greeneet al, 2008;McElligottet al, 2009;Nathwaniet al, 2009;Brightet al, 2010). Recently, we have shown that PBOX-15 induces apoptosis inex vivoB-cell chronic lymphocytic leukaemia (CLL) cells harbouring poor prognostic indicators and fludarabine resistance-associated p53 deletions (McElligottet al, 2009), and in imatinib-resistant chronic myeloid leukaemia (CML) cells (Brightet al, 2010). Importantly, PBOX-15 displays minimal toxicity towards normal blood and bone marrow cells (McElligottet al, 2009). The anticancer activity of drugs that interfere with tubulin dynamics, collectively known as microtubule targeting agents (MTA), is usually well established and, conventionally, Rabbit Polyclonal to GPRIN2 the proapoptotic activity of these agents has been linked to their induction of mitotic arrest (Jordan and Wilson, 2004;Zelnak, 2007). However, it is becoming increasingly clear that additional mechanisms leading to cell death may also be activated by these brokers (Gascoigne and Taylor, 2008), and indeed we have shown that PBOX-15 induces apoptosis impartial of cell cycle arrest inex vivoCLL cells (McElligottet al, 2009). In this study, we investigate the efficacy and mode of action of PBOX-15 in multiple myeloma, a common B-cell malignancy. Myeloma is usually characterised by the accumulation of malignant plasma cells with defective apoptotic mechanisms and minimal proliferative rates (Kuehl and Bergsagel, 2005). Current chemotherapy options include the proteasome inhibitor bortezomib, thalidomide, or its immunomodulatory analogue lenalidomide, in combination with steroids and DNA alkylating brokers (Kyle and Rajkumar, 2008). However, a major drawback of these brokers is the eventual development of resistance. Of particular concern is the emergence of resistance to bortezomib and lenalidomide in myeloma patients (Politouet al, 2006;Schmidmaieret al, 2007;Sonneveldet al, 2008). Therefore, there is a pressing need for continued investigation and development of option treatment options for patients. The MTA vincristine has also exhibited therapeutic efficacy in myeloma, and has previously been incorporated into initial treatment regimes for newly diagnosed patients (Alexanianet al, 1990). However, its use is usually associated with the development of multidrug resistance, and it has largely been replaced by newer brokers (Groganet al, 1993;Kyle and Rajkumar, 2008). A number of preclinical studies have exhibited the anti-myeloma activity of other MTAs, including Taxol, Vinorelbine (a semisynthetic Vinca alkaloid), and the isocourmarin derivative 185322 (Aoyamaet al, 1998;Ochiaiet al, 2002;Kawanoet al, 2007). In addition, 5HPP-33, a thalidomide analogue with potent anti-myeloma activity, has also exhibited tubulin-polymerisation-inhibiting activityin vitro(Kizaki and Hashimoto, 2008). In this study, we demonstrate the anti-myeloma activity of PBOX-15 in a panel of myeloma cell lines and in main myeloma cellsex vivo. Moreover, we delineate the mechanism AVL-292 benzenesulfonate of PBOX-15 activity in myeloma cells: we show induction of caspase-8-dependent apoptosis, impartial activation of the extrinsic and intrinsic apoptotic pathways, and early downregulation of the proapoptotic BH3-only protein Bim. Importantly, we show upregulation of death receptor 5 (DR5) in AVL-292 benzenesulfonate PBOX-15-treated myeloma cells, with resultant potentiation of apoptosis following cotreatment with PBOX-15 and the DR5 ligand, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). == Materials and methods == == Chemicals == PBOX-15 was AVL-292 benzenesulfonate synthesised as previously explained (Campianiet al, 1996;Mc Geeet al, 2005).KillerTRAIL was obtained from Alexis Biochemicals (Lausen, Switzerland) and caspase inhibitors were obtained from Calbiochem (Darmstadt, Germany). Unless indicated, all other reagents and chemicals were obtained from Sigma-Aldrich (St Louis, MO, USA). == Cell culture == NCI-H929, U266, and RPMI8226 myeloma cell lines were obtained from the DSMZ cell lender (Braunschweig, Germany). KMS11 cells (Nambaet al, 1989) were a kind gift from Dr Takemi Otsuki, Kawasaki Medical School, Japan. All cell lines were cultured in total medium (RPMI-1640 medium supplemented with 10% fetal calf serum and 1% penicillinstreptomycin) under standard cell culture conditions. == Patient samples == Written.